Cargando…

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia

Detalles Bibliográficos
Autores principales:	Wullenkord, Ramona, Reicherts, Christian, Mikesch, Jan-Henrik, Marx, Julia, Wethmar, Klaus, Albring, Jörn, Call, Simon, Lenz, Georg, Stelljes, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817557/ https://www.ncbi.nlm.nih.gov/pubmed/32829460 http://dx.doi.org/10.1007/s00277-020-04227-8

Ejemplares similares

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ueda, Tomoaki, et al.
Publicado: (2022)

Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2023)

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Song, Jinlin, et al.
Publicado: (2019)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
por: Reinert, Jochim, et al.
Publicado: (2021)

Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019)

Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018)

Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicin
por: Silva, Wellington Fernandes da, et al.
Publicado: (2019)

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
por: Stock, Wendy, et al.
Publicado: (2020)

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018)

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
por: Delea, Thomas E., et al.
Publicado: (2019)

P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
por: Russell-Smith, A., et al.
Publicado: (2022)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Garrett, May, et al.
Publicado: (2019)

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
por: Marks, David I., et al.
Publicado: (2019)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Aujla, Amandeep, et al.
Publicado: (2019)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review
por: Kebriaei, Partow, et al.
Publicado: (2018)

Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases
por: Okura, Miyuki, et al.
Publicado: (2020)

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Chen, Joseph, et al.
Publicado: (2020)

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
por: Ravaioli, Federico, et al.
Publicado: (2021)

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
por: Rubinstein, Jeremy D., et al.
Publicado: (2023)

Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden
por: van Oostrum, I., et al.
Publicado: (2021)

Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
por: Pennesi, Edoardo, et al.
Publicado: (2022)

CD22(low)/Bcl-2(high) expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia
por: Wintering, Astrid, et al.
Publicado: (2022)

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
por: Wieduwilt, Matthew, et al.
Publicado: (2023)

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
por: Yurkiewicz, Ilana R, et al.
Publicado: (2018)

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
por: Kantarjian, Hagop M., et al.
Publicado: (2019)

Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Micheva, Ilina, et al.
Publicado: (2021)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents
por: Maristany, Sumiko, et al.
Publicado: (2022)

PB1756: INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCE
por: Antipova, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c3ki4udu9dau92p2mu3gnhu3ng